ArticlePharmacogenomics and personalized medicine2008
Integrating Epigenomics into Pharmacogenomic Studies.
Article in Pharmacogenomics and personalized medicine, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Pharmaco-Epigenetics and Epigenetic Drugs in Type 2 Diabetes: Can Epigenetics Predict Drug Efficiency?Biomedicines · 2025Review
- Discrepancies in Recommendations on Pharmacokinetic Drug Interactions for Anticancer Medications and Direct Oral Anticoagulants (DOAC): A Comparative Analysis of Different Clinical Decision Support Systems and Sources.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Population Pharmacogenomics in Croatia: Evaluating the PGx Allele Frequency and the Impact of Treatment Efficiency.International journal of molecular sciences · 2023Article
- Knowledge, attitudes, and perceptions of the multi-ethnic population of the United Arab Emirates on genomic medicine and genetic testing.Human genomics · 2023Article
- Experience with comprehensive pharmacogenomic multi-gene panel in clinical practice: a retrospective single-center study.Croatian medical journal · 2022Article
- Observational
- Development of a 3D Printed Coating Shell to Control the Drug Release of Encapsulated Immediate-Release Tablets.Polymers · 2020Article
- Pharmacogenomics And Hypertension: Current Insights.Pharmacogenomics and personalized medicine · 2019Review
- Pharmacogenetics of antiplatelet therapy.Current atherosclerosis reports · 2014Review
- Pharmacogenomic Discovery Delineating the Genetic Basis of Drug Response.Current genetic medicine reports · 2013Article
- Cancer pharmacogenomics: strategies and challenges.Nature reviews. Genetics · 2013Review
- Lymphoblastoid cell lines in pharmacogenomic discovery and clinical translation.Pharmacogenomics · 2012Review
- Article
- MicroRNA signatures associated with immortalization of EBV-transformed lymphoblastoid cell lines and their clinical traits.Cell proliferation · 2011Article
- The emerging role of microRNAs in drug responses.Current opinion in molecular therapeutics · 2010Review
- Impact of the 1000 genomes project on the next wave of pharmacogenomic discovery.Pharmacogenomics · 2010Review
- SCAN: SNP and copy number annotation.Bioinformatics (Oxford, England) · 2010Article
- Pharmacogenetics in breast cancer: steps toward personalized medicine in breast cancer management.Pharmacogenomics and personalized medicine · 2010Article
- Exploring the relationship between polymorphic (TG/CA)n repeats in intron 1 regions and gene expression.Human genomics · 2009Article
- Pharmacogenomics in type II diabetes mellitus management: Steps toward personalized medicine.Pharmacogenomics and personalized medicine · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The goal of personalized medicine is to recommend drug treatment based on an individual's genetic makeup. Pharmacogenomic studies utilize two main approaches: candidate gene and whole-genome. Both approaches analyze genetic variants such as single nucleotide polymorphisms (SNPs) to identify associations with drug response. In addition to DNA sequence variations, non-genetic but heritable epigenetic systems have also been implicated in regulating gene expression that could influence drug response. The International HapMap Project lymphoblastoid cell lines (LCLs) have been used to study genetic determinants responsible for expression variation and drug response. Recent studies have demonstrated that common genetic variants, including both SNPs and copy number variants (CNVs) account for a substantial fraction of natural variation in gene expression. Given the critical role played by DNA methylation in gene regulation and the fact that DNA methylation is currently the most studied epigenetic system, we suggest that profiling the variation in DNA methylation in the HapMap samples will provide new insights into the regulation of gene expression as well as the mechanisms of individual drug response at a new level of complexity. Epigenomics will substantially add to our knowledge of how genetics explains gene expression and pharmacogenomics.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.